Cover Image

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.Methods:EGFR+ NSCLC patients treated with first/second-generation (1G/2G)...

Full description

Saved in:
Bibliographic Details
Main Authors: Magios, Nikolaus (Author) , Bozorgmehr, Farastuk (Author) , Volckmar, Anna-Lena (Author) , Kazdal, Daniel (Author) , Kirchner, Martina (Author) , Herth, Felix (Author) , Heußel, Claus Peter (Author) , Eichhorn, Florian (Author) , Meister, Michael (Author) , Muley, Thomas (Author) , El-Shafie, Rami (Author) , Fischer, Jürgen (Author) , Faehling, Martin (Author) , Kriegsmann, Mark (Author) , Schirmacher, Peter (Author) , Bischoff, Helge (Author) , Stenzinger, Albrecht (Author) , Thomas, Michael (Author) , Christopoulos, Petros (Author)
Format: Article (Journal)
Language:English
Published: March 24, 2021
In: Therapeutic advances in medical oncology
Year: 2021, Volume: 13, Pages: 1-13
ISSN:1758-8359
DOI:10.1177/1758835921996509
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/1758835921996509
Get full text
Author Notes:Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos
Description
Summary:Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging.Methods:EGFR+ NSCLC patients treated with first/second-generation (1G/2G) TKI at our institution with a last follow-up after osimertinib approval (February 2016), were analyzed retrospectively, and the results compared with published data under osimertinib.Results:A total of 207 patients received erlotinib (37%), gefitinib (16%) or afatinib (47%). The median age was 66?years, with a predominance of female (70%), never/light-smokers (69%). T790M testing was performed in 174/202 progressive cases (86%), positive in 93/174 (53%), and followed by osimertinib in 87/93 (94%). Among the 135 deceased patients, 94 (70%) received subsequent systemic treatment (43% chemotherapy, 39% osimertinib), while 30% died without, either before (4%) or after progression, due to rapid clinical deterioration (22%), patient refusal of further therapy (2%), or severe competing illness (2%). Lack of subsequent treatment was significantly (4.5x, p?
Item Description:Gesehen am 12.06.2021
Physical Description:Online Resource
ISSN:1758-8359
DOI:10.1177/1758835921996509

Similar Items